West Pharmaceutical Services, Inc. filed its Form 10-Q with the SEC on October 29, 2026, covering the quarterly period ended September 30, 2026.

Key Highlights

  • Net sales of $874.5 million for the three months ended September 30, 2026, compared to $804.6 million in the same period of 2025, according to the filing.
  • Net income of $214.0 million for Q3 2026, up from $140.0 million in Q3 2025, as reported in the condensed consolidated statements of income.
  • Diluted EPS of $3.02 for the three months ended September 30, 2026, versus $1.92 in the prior-year quarter.
  • $685.3 million in shares repurchased under share repurchase programs during the nine months ended September 30, 2026, compared to $134.0 million in the same period of 2025.
  • Gain on sale of SmartDose® 3.5mL On-Body Delivery System of $55.7 million recorded as a non-cash adjustment in the nine-month cash flow statement.
  • Cash and cash equivalents of $464.1 million at September 30, 2026, down from $791.3 million at December 31, 2025.
  • 69,661,036 shares outstanding as of October 21, 2026, as disclosed on the filing's cover page.

West Pharmaceutical Services Third-Quarter 2026 Financial Results

According to the Form 10-Q filed with the SEC, West Pharmaceutical Services (NYSE:WST) reported net sales of $874.5 million for the three months ended September 30, 2026, compared to $804.6 million for the same period in 2025. For the nine months ended September 30, 2026, net sales totaled $2,591.7 million versus $2,269.1 million in the prior-year period. Gross profit for the third quarter was $347.4 million, up from $294.3 million a year earlier, the filing disclosed.

The filing reported operating profit of $267.4 million for Q3 2026, compared to $167.6 million in Q3 2025. The company noted other expense (income) of $(51.2) million in the three-month period, which contrasted with $6.9 million of expense in the same quarter of the prior year. For the nine-month period, the company disclosed operating profit of $623.6 million against $428.3 million in 2025. Income tax expense for the nine months ended September 30, 2026 was $134.9 million, compared to $88.3 million a year prior.

The condensed consolidated balance sheet shows total assets of $4,060.7 million at September 30, 2026, compared to $4,270.0 million at December 31, 2025. Treasury stock increased to $(1,730.4) million, reflecting 5.5 million shares held, up from 3.3 million shares and $(1,112.2) million at year-end 2025. The cash flow statement shows net cash provided by operating activities of $403.4 million for the nine months ended September 30, 2026, versus $503.7 million in the comparable 2025 period. Capital expenditures were $125.0 million for the nine-month period, down from $209.8 million in 2025. Proceeds from sale of assets were $126.9 million, with a related disbursement of $8.9 million, according to the filing.

What Was Disclosed

West Pharmaceutical Services filed its quarterly report for the period ended September 30, 2026, disclosing income statements, balance sheets, and cash flow data for the three- and nine-month periods, as well as share repurchase activity and a gain on the sale of the SmartDose® 3.5mL On-Body Delivery System.